

# UCORE RARE METALS INC. (A Development-Stage Enterprise)

**Unaudited Condensed Interim Consolidated Financial Statements** 

Second Quarter
For the three and six-month period ended June 30, 2022

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, then such financial statements must be accompanied by a notice to this effect. Management of Ucore Rare Metals Inc. has prepared these condensed interim consolidated financial statements. Management has compiled the unaudited condensed interim consolidated statement of financial position of Ucore Rare Metals Inc. as at June 30, 2022, the audited condensed consolidated statement of financial position as at December 31, 2021 and the unaudited condensed interim consolidated statements of comprehensive loss, changes in shareholder's equity and cash flows for the three and six-month periods ended June 30, 2022 and June 30, 2021. The Company's independent auditors have not audited, reviewed or otherwise attempted to verify the accuracy or completeness of the June 30, 2022 condensed interim consolidated financial statements. Readers are cautioned that these statements may not be appropriate for their intended purposes.

Condensed Interim Consolidated Statements of Financial Position

Expressed in Canadian dollars

(Unaudited - Prepared by Management)

	June 30	December 31,
	2022	2021
	\$	\$
ASSETS		
Current assets		
Cash	712,597	3,331,164
Marketable securities	1,250	1,000
Receivables (note 6)	409,758	292,670
Prepaid expenses and other	153,913	233,347
	1,277,518	3,858,181
Other asset	65,110	55,995
Plant and equipment (note 7)	108,339	72,935
Right-of-use asset (note 9)	118,219	162,551
Intellectual property (note 10)	8,089,154	8,089,154
Resource properties and related exploration costs (note 11)	38,280,809	37,205,010
	47,939,149	49,443,826
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued liabilities	1,307,408	902,837
Current portion of lease liability (note 12)	98,422	91,353
Convertible debentures (note 14)	1,127,018	
	2,532,848	994,190
Long-term liabilities		
Lease liability (note 12)	36,205	87,250
Loan payable (note 13)	1,148,779	1,103,025
Convertible debentures (note 14)		1,231,609
	3,717,832	3,416,074
Shareholders' equity		
Share capital (note 15)	84,252,990	84,252,990
Contributed surplus (note 15)	24,576,373	24,033,093
Warrants (note 15)	2,746,559	3,178,387
Accumulated other comprehensive income	4,240,615	3,888,978
Deficit	(71,595,220)	(69,325,696)
	44,221,317	46,027,752
	47,939,149	49,443,826

Going concern (note 2)

Subsequent events (note 19)

## Approved on behalf of the Board of Directors

(s) Patrick Ryan
Patrick Ryan, CEO and Director

(s) Geoff Clarke

Geoff Clarke, Director

•

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss Expressed in Canadian dollars
For the quarters ended June 30
(Unaudited - Prepared by Management)

	For the Three	Months	For the Six N	Months
	Ended Jun	e 30	Ended Jun	e 30
_	2022	2021	2022	2021
	\$	\$	\$	\$
EXPENSES				
Amortization	23,936	28,208	57,002	55,893
Investor relations and marketing	89,298	84,785	152,773	131,136
Office and premises	53,733	65,688	121,284	153,582
Professional services	195,886	148,624	360,783	353,182
Salaries and consultants	349,543	689,425	869,096	1,203,673
Securities and regulatory	40,654	29,782	53,717	52,937
Research and development	244,523	101,970	432,103	416,619
Share-based payments (recovery) (note 15)	(2,121)	82,291	111,452	122,271
Travel	38,427	1,916	56,223	2,784
-	1,033,879	1,232,689	2,214,433	2,492,077
OTHER INCOME (EXPENSES)				
Interest income	-	3,894	126	4,878
Interest and accretion expense	(110,321)	(109,931)	(217,927)	(246,355)
Loss on the conversion of convertible debentures (note 14)	-	-	-	(533,941)
Fair value adjustment of derivative liabilities (note 14)	202,570	120,074	179,925	(503,129)
Gain on the sale of the MRT pilot plant (note 8)	-	-	-	1,491,545
Foreign exchange	(33,958)	8,338	(17,215)	41,726
-	58,291	22,375	(55,091)	254,724
NET LOSS	(975,588)	(1,210,314)	(2,269,524)	(2,237,353)
Net Loss per share - basic and diluted	(0.02)	(0.03)	(0.05)	(0.05)
Weighted average number of basic and diluted common shares outstanding	49,084,130	47,796,634	49,084,130	44,172,939
COMPREHENSIVE LOSS:				
Net loss for the period	(975,588)	(1,210,314)	(2,269,524)	(2,237,353)
Items which may be subsequently recycled through	(0.0)000)	(-///	(=/===/== :/	(-//
profit or loss				
Foreign currency translation difference arising on				
translation of foreign subsidiaries	699,894	(352,845)	351,387	(622,704)
Unrealized gain (loss) on available-for-sale securities	(250)	-	250	-
	(275,944)	(1,563,159)	(1,917,887)	(2,860,057)
<b>-</b>	, -,- ,	,,	, , , ,	, ,,,

 $The \, accompanying \, notes \, form \, an \, integral \, part \, of \, these \, condensed \, interim \, consolidated \, financial \, statements.$ 

Condensed Interim Consolidated Statements of Changes in Equity Expressed in Canadian dollars
(Unaudited - Prepared by Management)

_	Number of Shares	Share Capital	(	Contributed Surplus	Warrants	C	Accumulated Other omprehensive ncome (Loss)	Deficit	Total Equity
Balance at January 1, 2021	41,049,981	\$ 75,965,504	\$	22,799,469	\$ 2,641,188	\$	3,821,362	\$ (63,814,949)	\$ 41,412,574
Net loss	-	-		-	-		-	(2,237,353)	(2,237,353)
Foreign currency translation adjustment	-	-		-	-		(622,704)	-	(622,704)
Financing (net of costs)	6,700,000	4,776,664		-	1,794,346		-	-	6,571,010
Shares issued on the exercise of warrants	46,666	106,693		-	(22,695)		-	-	83,998
Shares and warrants issued on the conversion of convertible									
debentures	1,287,483	1,980,053		-	624,470		-	-	2,604,523
Expiry of warrants	-	-		447,852	(447,852)		-	-	-
Share-based payments	=	-		122,271	-		-	-	122,271
Balance at June 30, 2021	49,084,130	\$ 82,828,914	\$	23,369,592	\$ 4,589,457	\$	3,198,658	\$ (66,052,302)	\$ 47,934,319
Balance at January 1, 2022	49,084,130	\$ 84,252,990	\$	24,033,093	\$ 3,178,387	\$	3,888,978	\$ (69,325,696)	\$ 46,027,752
Net loss	-	_		_	-		_	(2,269,524)	(2,269,524)
Unrealized gain (loss) on available for sale securities	_	-		-	-		250	-	250
Foreign currency translation adjustment	-	-		-	-		351,387	-	351,387
Expiry of warrants (note 15)	-	-		431,828	(431,828)		- -	-	· -
Share-based payments (note 15)	-	-		111,452	-		-	-	111,452
Balance at June 30, 2022	49,084,130	\$ 84,252,990	\$	24,576,373	\$ 2,746,559	\$	4,240,615	\$ (71,595,220)	\$ 44,221,317

The accompanying notes form an integral part of these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Cash Flows Expressed in Canadian dollars For the six months ended June 30 (Unaudited - Prepared by Management)

	2022	2021
	\$	\$
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES	( )	()
Net loss for the period	(2,269,524)	(2,237,353)
Adjustments and items not involving cash:		
Amortization	57,002	55,893
Amortization recorded in research and development	15,229	<u>-</u>
Change in fair value of derivative liability (note 14)	(179,925)	503,129
Loss on the conversion of convertible debentures (note 14)	-	533,941
Share-based payments (note 15)	111,452	122,271
Accretion expense	115,191	132,078
Proceeds from the sale of the MRT pilot plant (note 8)	-	(939,844)
Unrealized gain (loss) on available-for-sale securities	-	26,833
Unrealized foreign exchange (gain) loss	15,891	(30,212)
	(2,134,684)	(1,833,264)
Change in non-cash operating working capital:		
Receivables	(117,088)	(524,989)
Prepaid expenses and other	83,004	(27,540)
Accounts payable and accrued liabilities	(100,328)	(363,349)
Cash flow used in operating activities	(2,269,096)	(2,749,142)
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES		
Interest paid on lease liabilities (note 12)	(11,349)	(17,437)
Repayment of lease liabilities (note 12)	(43,976)	(37,885)
Proceeds from the issuance of common shares (net of costs) (note 15)	-	6,571,010
Issuance of common shares on exercise of warrants (note 15)	<u> </u>	83,998
Cash flows (used in) from financing activities	(55,325)	6,599,686
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES		
Purchase of plant and equipment	(63,303)	(5,237)
Proceeds from the sale of the MRT pilot plant (note 8)	-	939,844
Additions to other asset	(8,986)	-
Additions to resource properties and related exploration costs	(223,082)	(137,652)
Cash flows from (used in) investing activities	(295,371)	796,955
cash nows from (asea in) investing activities	(233,371)	730,333
INCREASE (DECREASE) IN CASH	(2,619,792)	4,647,499
Foreign exchange impact on cash	1,225	(1,412)
CASH, beginning of period	3,331,164	1,008,838
CASH, end of period	712,597	5,654,925

Supplementary Cash Flow Information (note 18)

The accompanying notes form an integral part of these condensed interim consolidated financial statements.

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 1. NATURE OF OPERATIONS

Ucore Rare Metals Inc. ("Ucore" or the "Company") is a corporation domiciled in Canada and it is registered and existing pursuant to the *Business Corporations Act* (Alberta). The address of the Company's head office is 210 Waterfront Drive, Suite 106, Halifax Nova Scotia, B4A 0H3. The Company is focused on rare and critical metal resources, extraction, beneficiation, and separation technologies with the potential for production, growth and scalability. The Company has an effective 100-percent ownership stake in the Bokan-Dotson Ridge rare earth element project in southeast Alaska, United States (see note 11). The Company's vision and plan is to become a leading advanced technology company, providing best-in-class metal separation products and services to the mining and mineral extraction industry. Through strategic partnerships, the Company's vision includes disrupting the People's Republic of China's (PRC) control of the United States rare earth element supply chain through the development of a heavy rare earth processing facility -- the Alaska strategic metals complex in southeast Alaska and the long-term development of the Company's heavy rare earth element mineral resource property located at Bokan Mountain on Prince of Wales Island, Alaska. To date, the Company has not earned significant revenues and is considered to be a development stage enterprise.

On May 8, 2020, the Company acquired 100% of the issued and outstanding shares of Innovation Metals Corp. ("IMC"), the developer of its proprietary RapidSX<sup>TM</sup> process for the low-cost separation and purification of rare earth elements ("REEs"), nickel ("Ni"), cobalt ("Co"), lithium ("Li") and other technology metals, via an accelerated form of solvent extraction. IMC is commercializing this approach for a number of metals, to help enable mining and metal-recycling companies to compete in today's global marketplace.

#### 2. GOING CONCERN

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to a going concern, which assumes the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but is not limited to, twelve months from the end of the reporting period. Management is aware, in making its assessment, of material uncertainties related to events or conditions that may cast significant doubt upon the Company's ability to continue as a going concern, as described in the following paragraphs.

The Company has no sources of revenue, experienced significant losses and negative cash flows from operations in 2022 and 2021 and has a deficit. Management estimates current working capital may not be sufficient to fund all of the Company's planned expenditures in 2022. The ability of the Company to continue as a going concern, realize its assets and discharge its liabilities in the normal course of business, expand upon its exploration and development programs, and advance the Company's RapidSX<sup>™</sup> technology is contingent upon securing financing or monetizing assets. The timing and availability of additional financing will be determined largely by market conditions, the results of the Company's ongoing exploration and development programs, and the advancement of Company's RapidSX<sup>™</sup> technology. There is no certainty that the Company will be able to raise funds as they are required in the future.

These financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern basis was not appropriate for these financial statements, then adjustments would be necessary to the carrying value of assets and liabilities, the reported revenues and expenses, and the statement of financial position classifications used.

In March 2020 the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. Management is actively monitoring the effect of the pandemic on its financial condition, liquidity, operations, supplies, and workforce. Given the daily evolution of the pandemic and the global response to curb its spread the Company is not able to predict its effects on the Company's business liquidity or ability to raise funds.

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 3. BASIS OF PRESENTATION

#### Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with IFRS applicable to the preparation of interim financial statements, including IAS 34 *Interim Financial Reporting*.

The date the Board of Directors approved the financial statements is August 29, 2022.

#### Basis of measurement

These condensed interim consolidated financial statements have been prepared using the historical cost basis except for certain financial instruments that have been measured at fair value. All intercompany transactions, balances, and expenses are eliminated on consolidation.

Items included in the financial statements of each of the Company's subsidiaries are measured using the currency of the primary economic environment in which the entity operates ("functional currency"). The condensed interim consolidated financial statements are presented in Canadian dollars, which is the functional and presentation currency of the Company.

#### Use of estimates and judgments

The preparation of financial statements requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. These estimates are based on historical experience, current and future economic conditions, and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The determination of estimates requires the exercise of judgments based on various assumptions and other factors such as historical experience and current and expected economic conditions. Actual results could differ from those estimates.

The use of estimates and judgments are the same as those applied in the Company's consolidated financial statements as at and for the year ended December 31, 2021.

#### 4. ACCOUNTING CHANGES AND RECENT PRONOUNCEMENTS

The accounting policies applied in these condensed interim consolidated financial statements are the same as those applied in the Company's consolidated financial statements as at and for the year ended December 31, 2021.

New accounting standards not yet adopted

The IASB issued the following standards that have not been applied in preparing these consolidated financial statements as their effective date falls within annual periods beginning subsequent to the current reporting period.

#### IAS 1 – Presentation of Financial Statements

On January 23, 2020, the IASB issued an amendment to IAS 1 Presentation of Financial Statements providing a more general approach to the classification of liabilities. The amendment clarifies that the classification of liabilities as current or noncurrent depends on the rights existing at the end of the reporting period as opposed to the expectations of exercising the right for settlement of the liability. The amendments further clarify that settlement refers to the transfer of cash, equity instruments, other assets, or services to the counterparty. The amendments are effective for annual periods beginning on or after January 1, 2023 and are to be applied retrospectively, with early adoption permitted. The Company is currently assessing the financial impact of the amendments and expects to apply the amendments at the effective date.

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 4. ACCOUNTING CHANGES AND RECENT PRONOUNCEMENTS (continued)

The Company adopted the following accounting standards and amendments to accounting standards effective January 1, 2022:

#### IAS 16 – Property, Plant and Equipment

On May 14, 2020, the IASB issued an amendment to IAS 16 Property, Plant and Equipment to prohibit deducting from the cost of an item of property, plant and equipment, any proceeds from selling items produced while bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. The proceeds from selling such items, and the cost of producing those items are to be recognized in profit and loss. The amendments are effective for annual periods beginning on or after January 1, 2022 with early adoption permitted. The amendment is to be applied retrospectively only to items of property, plant and equipment that are brought to the location and condition necessary for them to be capable of operating in the manner intended by management on or after the earliest period presented in the financial statements in the year in which the amendments are first applied. These amendments had no impact on the Company's condensed interim consolidated financial statements.

#### IAS 37 – Provisions, Contingent Liabilities and Contingent Assets

On May 14, 2020, the IASB issued an amendment to IAS 37 Provisions, Contingent Liabilities and Contingent Assets to specify which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. The amendment specifies that the cost of fulfilling a contract comprises the costs that relate directly to the contract. Costs that relate directly to the contract can either be incremental costs of fulfilling the contract or an allocation of other costs that relate directly to fulfilling contracts. The amendments are effective for contracts for which the Company has not yet fulfilled all its obligations on or after January 1, 2022 with early adoption permitted. These amendments had no impact on the Company's condensed interim consolidated financial statements.

#### IFRS 9 - Financial Instruments

On May 14, 2020, the IASB issued an amendment to IFRS 9 Financial Instruments clarifying which fees to include in the test in assessing whether to derecognize a financial liability. Only those fees paid or received between the borrower and the lender, including fees paid or received by either the entity or the lender on the other's behalf are included. The amendment is effective for annual periods beginning on or after January 1, 2022 with early adoption permitted. These amendments had no impact on the Company's condensed interim consolidated financial statements.

## 5. CAPITAL MANAGEMENT

The Company's capital at June 30, 2022 consists of shareholders' equity of \$44,221,317 (December 31, 2021 - \$46,027,752). The Company's objective when managing capital is to maintain adequate levels of funding to support the acquisition and exploration of resources properties, the advancement of the Company's prospective separation technology, and maintain the necessary corporate and administrative functions to facilitate these activities. This is done primarily through equity and debt based financings. Future financings are dependent on market conditions, and there can be no assurance the Company will be able to raise funds in the future.

The Company invests all capital that is surplus to its immediate operational needs in a high interest savings account. There were no changes to the Company's approach to capital management during the period. The Company is not subject to externally imposed capital requirements.

#### 6. RECEIVABLES

As at June 30, 2022, receivables include \$228,910, (2021 - \$292,670) of Good and Services Tax / Harmonized Sales Tax ("GST") due from government taxation authorities. As at June 30, 2022 the Company had a SR&ED tax credit receivable of \$95,838 relating to tax credits claimed from prior years. As at June 30, 2022 the Company has estimated its SR&ED tax credits for the period ended June 30, 2022 to be a recovery of \$85,010. To the extent the SR&ED claim is adjusted and accepted, it will impact the amount of the tax credit receivable, tax losses and undeducted SR&ED costs carried forward.

Notes to Condensed Interim Consolidated Financial Statements

For the three and six month period ended June 30, 2022

#### 7. PLANT AND EQUIPMENT

	Office		Exploration		Research		
	Equipment		Equipment		Equipment		Total
Cost							
Balance, January 1, 2021	\$	253,233	\$	142,746	\$	24,000	\$ 419,979
Additions		3,097		-		43,043	46,140
Balance, December 31, 2021		256,330		142,746		67,043	466,119
Additions		950		-		62,353	63,303
Balance, June 30, 2022		257,280		142,746		129,396	529,422
Accumulated amortization							
Balance, January 1, 2021	\$	225,102	\$	140,786	\$	1,000	\$ 366,888
Amortization		9,027		155		17,114	26,296
Balance, December 31, 2021		234,129		140,941		18,114	393,184
Amortization		3,450		54		24,395	27,899
Balance, June 30, 2022		237,579		140,995		42,509	421,083
Net book value							
Balance, December 31, 2021	\$	22,201	\$	1,805	\$	48,929	\$ 72,935
Balance, June 30, 2022	\$	19,701	\$	1,751	\$	86,887	\$ 108,339

## 8. GAIN ON SALE OF THE MRT PILOT PLANT:

On February 19, 2021, the Company and its named individual officers and IBC Advanced Technologies Inc., its named individual officers and all IBC shareholders that are party to the Option to Purchase Agreement, reached a settlement agreement regarding all litigation activities between the parties and any other associated individuals. The terms included IBC purchasing the MRT pilot plant from the Company for \$1,491,545 (\$1,175,000 USD) pursuant to a series of payments which were all received during 2021. During the year ended December 31, 2019 the Company recorded an impairment for the full cost of the MRT pilot plant of \$2,914,106. The payments received during the year ended December 31, 2021 where recorded through the statement of loss and comprehensive loss as a gain on the sale of the MRT pilot plant.

## 9. RIGHT OF USE ASSET

The Company recognized a right-of-use asset for the lease of the Company's head office located in Bedford, Nova Scotia.

Cost	
Balance, December 31, 2020	\$ 416,201
Additions	-
Balance, December 31, 2021	416,201
Additions	-
Balance, June 30, 2022	416,201
Depreciation	
Balance, December 31, 2020	\$ 164,986
Charge for the year	88,664
Balance, December 31, 2021	253,650
Charge for the period	44,332
Balance, June 30, 2022	297,982
Net book value	
Balance, December 31, 2021	\$ 162,551
Balance, June 30, 2022	\$ 118,219

Depreciation of right-of-use assets is calculated using the straight-line method over the remaining lease term.

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 10. INTELLECTUAL PROPERTY

On May 8, 2020, the Company acquired 100% of the issued and outstanding shares of Innovation Metals Corp. ("IMC"), a company focused on research and development of technologies for the separation of critical metals including rare earth elements, pursuant to the terms and conditions set forth in a share purchase agreement dated April 27, 2020. Management has assessed the acquisition of IMC to be an asset acquisition due to the concentration test. As part of the acquisition the Company acquired intellectual property with a value of \$8,089,154. The following table reconciles the changes attributable to the Company's intellectual property:

		December 31,					June 30
		2021		Additions	Amorization		2022
Intellectual property	\$	8,089,154	\$	-		-	\$ 8,089,154
		December 31,					December 31
		2020		Additions	Amorization		2021
Intellectual property	Ś	8.089.154	Ś	-	 ;	-	\$ 8.089.154

Amortization of the intellectual property will commence when the assets are available for commercial production.

#### 11. RESOURCE PROPERTIES AND RELATED EXPLORATION COSTS

The Company's interest in resource properties and related exploration costs consist of the following:

			Deferred		Movement							
	December 31,		exploration		in exchange	June 30						
	2021		costs		rates	2022						
Bokan Mountain, Alaska	\$ 37,205,010	\$	724,412		724,412		724,412		724,412		351,387	\$ 38,280,809
			Deferred		Movement							
	December 31,		exploration		in exchange	December 31						
	2020		costs		rates	2021						
Bokan Mountain, Alaska	\$ 36,838,028	\$	299,366	\$	67,616	\$ 37,205,010						

#### 12. LEASE LIABILITIES

In February 2012, the Company entered into a five-year operating lease for its head office premises in Halifax, Nova Scotia which began in October 2012. This lease was extended until October 2020 and further extended to October 2023. The Company is required to make monthly lease payments of \$9,221 per month until the expiration of the lease. The Company entered into a lease for a research facility in Salt Lake City, Utah in February 2016 which expired in January 2019. This lease was extended until July 2019 and then extend into a month-to-month lease with three months' notice to terminate the lease. The Company formally terminated this lease in March 2021. The Company's subsidiary, IMC, entered into a research facility lease in Kingston, Ontario in June 2020 which either party can terminate with 60 days' notice.

The following table reconciles the changes attributable to the Company's finance lease obligations:

	D	ecember 31,			Principal	Current		June 30,
		2021	Addit	ions	payments	portion		2022
Office lease liability	\$	178,603	\$	-	\$ (43,976)	\$ (98,422)	\$	36,205
	\$	178,603	\$	-	\$ (43,976)	\$ (98,422)	\$	36,205
	D	ecember 31,			Principal	Current	Dec	ember 31,
		2020	Addit	ions	payments	portion		2021
Office lease liability	\$	257,303	\$	-	\$ (78,700)	\$ (91,353)	\$	87,250
	\$	257,303	\$	-	\$ (78,700)	\$ (91,353)	\$	87,250

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 13. LOAN PAYABLE

On March 30, 2019, the Company entered into a secured loan agreement with Orca Holdings, LLC ("Orca"), a related party, in the amount of \$3,637,875 (\$2,725,000 USD) (the "Orca Loan"). Proceeds were used to repurchase the MRT Pilot Plant for \$2,670,000 (\$2,000,000 USD) and settle the related lease liability, settle accrued and unpaid lease payments totalling \$133,500 (\$100,000 USD); settlement of the remaining lease payments for the period April 1, 2019 to June 30, 2019 of \$100,132 (\$75,000 USD), settle payment of \$400,500 (\$300,000 USD) under a consulting agreement with Orca, and provide the Company with cash of \$333,750 (\$250,000 USD).

A discount on loan payable was determined to be \$194,869 which was recorded in the 2019 statement of loss. The discount represents the fair value adjustment on the loan. Interest was payable monthly and the principal amount was to be repaid in full on March 31, 2021. The loan had an interest at a rate of 12.5% annually for the first 9 months commencing July 1, 2019 and then a rate of 15% annually for the 12 months commencing April 1, 2020.

#### First Amended Orca Loan

On November 27, 2019, the Company renegotiated the Orca Loan. This included revised terms that saw the Company pay \$2,500,000 (\$1,890,696 USD) in principal and issue 500,000 share purchase warrants to Orca, extend the maturity date of the loan to November 30, 2021, and reduce the interest rate to 9% (the "Amended Orca Loan").

#### Second Amended Orca Loan

On November 29, 2021, the Company renegotiated the Orca Loan extending the maturity date by 24 months to November 30, 2023 and in conjunction with the extension the Company issued 1,000,000 share purchase warrants to Orca. Each share purchase warrant entitles Orca to acquire one common share of the Company at an exercise price of \$1.20 to November 30, 2023. The amendment was treated as an extinguishment and creation of a new debt instrument as the amendments resulted in a substantive change to the loan agreement.

The effective interest rate used to determine the fair value of the amended loan for initial recognition was 15%. The fair value of the warrants was determined to be \$403,063 using the Black -Scholes model using the following assumptions: (risk-free interest rate – 0.95%, expected life – 2.00 years, expected annual volatility – 108%, expected dividends – Nil, expected forfeiture rate – Nil.

	June 30,	December 31,
	2022	2021
Opening balance	\$ 1,103,025	\$ 1,166,159
Extinguishment of debt	-	(1,230,240)
Value of amended loan	-	1,103,003
Interest and accretion expense	28,508	66,680
Foreign exchange	17,246	(2,577)
Ending balance	\$ 1,148,779	\$ 1,103,025

As a result of the extension of the loan, the Company had a net gain of \$127,237 which, along with the fair value of the warrants issued of \$403,063, resulted in a loss-on-debt restructuring of \$275,827, which was incurred in Q4 2021. The loan balance is secured by a first charge on the Company's assets.

#### 14. CONVERTIBLE DEBENTURES

On May 21 and May 29, 2020, the Company issued 1,280 and 1,520 respectively, of convertible debentures, with a face value of \$1,000 each for total gross proceeds of \$2.8 million. The convertible debentures bear interest of 7.5% payable semi-annually and the principal amount matures on May 31, 2023. The Company has the option to extend the term to May 31, 2024 in the final year of the original term. If the Company elects to extend the term the Company shall pay an extension fee to the debenture holder in an amount equal to six months interest. The debenture holder has the right at any time on or prior to the maturity date to convert all or any portion of the outstanding principal into units of the Company at a conversion price of \$1.20 per unit. Each unit is comprised of one common share and one-half of one common share purchase warrant.

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 14. CONVERTIBLE DEBENTURES (continued)

Each whole warrant is exercisable by the holder to purchase one common share at an exercise price of \$1.80 per common share, exercisable until the maturity date of the debenture.

Should the common shares of the Company trade at a closing price of \$2.20 per common share or higher on the TSX Venture Exchange for twenty consecutive trading days, the debentures shall automatically convert into units at a conversion price of \$1.20 per unit.

In conjunction with the convertible debenture offering, the Company issued 140,000 commitment warrants. Each warrant entitles the holder to acquire one common share at an exercise price of \$1.80 per common share prior to May 31, 2022.

For accounting purposes, the debentures represent a hybrid financial instrument, consisting of a host loan obligation, and embedded derivative instruments comprising the conversions, extension and early conversion features of the debenture. The Company accounts for the host loan obligation at amortized cost, accrued to maturity over the term of the debenture. The embedded conversion and extension options are accounted for as a financial liability measured at fair value through profit or loss. The commitment warrants are accounted for as equity.

At the dates of issue, the convertible debentures and its components were measured at fair values, as follows:

	N	/lay 21, 2020	N	1a y 29, 2020	
		Tranche	Tranche		
Host liability component at issue	\$	813,114	\$	988,160	
Conversion and extension options at issue date		555,086		672,096	
Fair value of commitment warrants		202,964		244,550	
Loss on initial recognition		291,164		384,806	
Net proceeds from issue	\$	1,280,000	\$	1,520,000	

During the year ended December 31, 2021, 1,545 convertible debentures were converted to units. In connection with the conversion of convertible debentures into units the Company issued 1,287,483, common shares and 643,746 share purchase warrants. The fair value of the shares issued was calculated using the fair value of the common shares of the Company on the date of conversion. Using the Black Scholes pricing model, the Company determined the fair value of the warrants issued was \$624,470. The assumptions in the Black-Scholes pricing model used to calculate the fair value of the warrants issued was determined using the Black-Scholes pricing model using the following weight average assumptions: volatility of 124.19%, an expected life of 2.31 years, risk free rate of 0.23%, and a zero expected dividend yield.

A summary of the conversions during the period ended June 30, 2022 and year ended December 31, 2021 is provided below:

			Fair Value of			
	Principal	<b>Number of</b>	Common Shares	<b>Number of</b>	Fair Value of	
	Converted	Common Shares	Issued	Warrants	Warrants	Gain or (Loss)
Conversion Date	(\$)	Issued	(\$)	Issued	Issued (\$)	on Conversion
January 8, 2021	50,000	41,666	40,833	20,833	10,933	3,269
January 11, 2021	50,000	41,666	38,749	20,833	10,176	3,564
January 29, 2021	518,000	431,652	561,164	215,832	167,192	(71,984)
February 10, 2021	600,000	500,000	835,000	250,000	268,973	(254,182)
February 16, 2021	250,000	208,333	383,333	104,166	126,701	(173,003)
February 26, 2021	52,000	43,333	84,933	21,666	28,804	(30,375)
March 22, 2021	25,000	20,833	36,041	10,416	11,691	(11,230)
Total	1,545,000	1,287,483	1,980,053	643,746	624,470	(533,941)

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

## 14. CONVERTIBLE DEBENTURES (continued)

The following table summarizes the continuity of the host liability components of the loan:

	Ma	y 21, 2020	N	1a y 29, 2020	
	-	Γranche		Tranche	Total
Balance, December 31, 2020	\$	891,537	\$	1,075,694	\$ 1,967,231
Conversion of debentures		(872,661)		(216,335)	(1,088,996)
Accretion on discount		16,022		137,448	153,470
Balance, December 31, 2021	\$	34,898	\$	996,807	\$ 1,031,705
Accretion on discount		2,039		73,295	75,334
Balance, June 30, 2022	\$	36,937	\$	1,070,102	\$ 1,107,039

The following table summarizes the continuity of the conversion option components of the loan:

	M	ay 21, 2020	Ν	May 29, 2020	
		Tranche		Tranche	Total
Balance, December 31, 2020	\$	525,665	\$	624,227	\$ 1,149,892
Conversion of debentures		(792,545)		(189,042)	(981,587)
Fair value adjustment		272,455		(240,856)	31,599
Balance, December 31, 2021	\$	5,575	\$	194,329	\$ 199,904
Fair value adjustment		(1,595)		(178,330)	(179,925)
Balance, June 30, 2022	\$	3,980	\$	15,999	\$ 19,979

The fair value of the conversion options outstanding has been determined using a binomial option valuation model, using the following key assumptions:

	 Tranche 1 - I	May	21, 2020	Tranche 2 - I	29, 2020	
	June 30, December 31,		June 30,		December 31,	
	2022		2021	2022		2021
Expected volatility	60%		0.90%	60%		0.90%
Risk-free interest rate	2.41%		0.84%	2.41%		0.84%
Conversion option term	0.89 years		1.39 years	0.91 years		1.41 years
Creditspread	21.00%		20.69%	21.00%		20.69%
Underlying share price	\$ 0.64	\$	0.73	\$ 0.64	\$	0.73

#### 15. SHARE CAPITAL

#### Authorized:

Unlimited number of common voting shares

Unlimited number of first preferred non-voting shares issuable in series

Unlimited number of second preferred non-voting shares issuable in series

## a) Financing

On February 9, 2021, the Company closed a non-brokered private placement which consisted of an aggregate of 6.7 million units at a subscription price of \$1.00 per unit for aggregate gross proceeds to the Company of \$6.7 million.

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 15. SHARE CAPITAL (continued)

Each unit consists of one common share of the Company and one-half of one common share purchase warrant. Each warrant entitles the holder thereof to acquire one additional common share at a price of \$1.50 per share for a period of 36 months from the date of issuance, provided that, if, over a period of 10 consecutive trading days between the date that is four months and a day from the date of issuance of the warrants and the date that the warrants would otherwise expire, the closing price of the common shares on the TSX Venture Exchange is equal to or greater than \$1.75, then the Company may, at its option, elect to accelerate the expiry of the warrants by providing notice to the holders thereof within 10 calendar days following the end of such 10-consecutive-trading-day period, in which case the warrants will expire 30 calendar days following the end of such 10-consecutive-trading-day period. The Company determined that the fair value of the warrants issued was \$316,883. The fair value was determined using the Barrier Option pricing model. The assumptions used in the Barrier Option pricing model were: volatility of 111%, an expected life of 3 years, barrier price of \$1.75, risk-free rate of 0.24%, discount for lack of marketability of 25% to account for the warrants are nonmarketable interest.

The Company issued a total of 306,060 finder's units pursuant to certain subscriptions. Each finder's unit issued entitles the holder to acquire one common share of the Company and one-half of one common share purchase warrant. Each warrant entitles the holder thereof to acquire one additional common share at a price of \$1.50 per share for a period of 36 months from the date of issuance, provided that, if, over a period of 10 consecutive trading days between the date that is four months and a day from the date of issuance of the warrants and the date that the warrants would otherwise expire, the closing price of the common shares on the TSX Venture Exchange is equal to or greater than \$1.75, then the Company may, at its option, elect to accelerate the expiry of the warrants by providing notice to the holders thereof within 10 calendar days following the end of such 10-consecutive-trading-day period, in which case the warrants will expire 30 calendar days following the end of such 10-consecutive-trading-day period. The fair value of the warrants issued was \$86,049 which was determined using the Barrier Option pricing model. The assumptions used in the Barrier Option pricing model were: volatility of 111%, an expected life of 3 years, barrier price of \$0.75, discount for lack of marketability of 35% to account for the warrants are nonmarketable interest and non-transferability resulting in the following allocation of proceeds and costs between common shares and warrants. Other costs associated with the private placement totaled \$128,990.

A summary of the allocation of proceeds is provided below:

	 Allocation of proceeds							
	Shares	٧	Va rra nts		Total			
Proceeds	\$ 6,383,117	\$	316,883	\$	6,700,000			
Cash costs	(100,398)		(28,592)		(128,990)			
Finder's warrants	(81,979)		81,979		-			
Closing balance	\$ 6,200,740	\$	370,270	\$	6,571,010			

#### b) Stock options

For the six-month period ended June 30, 2022, the Company recognized share-based compensation of \$173,700 (2021 - \$122,271) for options granted to directors, employees, and consultants. The Company recorded a forfeiture recovery to share based compensation expense of \$62,248 (2021 - \$Nil). As a result of transactions during the period, \$111,452 (2021 - \$122,271) was charged to income.

Changes in stock options during the six month period ended June 30, 2022 and year ended December 31, 2021 are summarized below:

		Period ended June 30, 2022		Year ended
		December 31, 2021		
		Weighted average		Weighted average
	Number of	exercise price	Number of	exercise price
	options	\$	options	\$
Opening balance	2,329,000	1.81	1,829,000	2.22
Granted	-	-	790,000	1.28
Expired	-	-	(290,000)	3.01
Forfeited	(60,000)	1.30	-	<u>-</u>
Closing balance	2,269,000	1.82	2,329,000	1.81

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 15. SHARE CAPITAL (continued)

The fair value of options granted has been estimated using the Black-Scholes option pricing model. On March 26, 2021 the Company issued 190,000 options using the following option pricing model assumptions: risk free interest rate 0.93%, expected life of 3 years, volatility of 118%, dividend yield rate of zero, and a forfeiture rate of zero resulting in a weighted average grant date fair value of \$1.13 per stock option. On May 17, 2021, the Company issued 120,000 options using the following option pricing model assumptions: risk free rate 0.95%, expected life of 3 years, volatility of 118%, dividend yield rate of zero, and a forfeiture rate of zero resulting in a weighted average grant date fair value of \$0.79 per stock option. On September 1, 2021, the Company issued 480,000 options using the following option pricing model assumptions: risk free rate 0.79%, expected life of 3 years, volatility of 116%, dividend yield rate of zero, and a forfeiture rate of zero resulting in a weighted average grant date fair value of \$0.61 per stock option.

The following table summarizes information about the stock options outstanding and exercisable at June 30, 2022:

Exercise price per share	Number of		Number of
\$	outstanding options	Expiry Date	exercisable options
1.20	120,000	May 17, 2026	80,000
1.20	384,000	November 15, 2024	384,000
1.30	480,000	September 1, 2026	160,000
1.30	130,000	March 26, 2026	86,667
1.55	40,000	September 23, 2024	40,000
1.65	265,000	May 15, 2025	265,000
1.90	20,000	February 12, 2023	20,000
2.30	20,000	July 30, 2023	20,000
2.65	810,000	August 21, 2022	810,000
	2,269,000		1,865,667
Weighted average remaining life			1.82 years

As at June 30, 2022, there are 55,710 (December 31, 2021 – 55,710) deferred share units outstanding which have been fully vested.

#### c) Warrants:

Changes in share purchase warrants during the six month period ended June 30, 2022 and year ended December 31, 2021 are summarized as follows:

		Period ended June 30, 2022		Year ended December 31, 2021
		Weighted average		Weighted average
	Number of	exercise price	<b>Number of</b>	exercise price
	warrants	\$	warrants	\$
Opening balance	5,393,140	1.46	1,412,128	1.92
Granted	-	-	5,299,806	1.45
Exercised	-	-	(46,666)	1.80
Expired	(135,000)	1.80	(1,272,128)	1.94
Closing balance	5,258,140	1.45	5,393,140	1.46
Weighted average remaining life		1.50 years		1.95 years

During the six-month period ended June 30, 2022, 135,000 (December 31, 2021 - 1,272,128) warrants expired unexercised. This resulted in an increase to contributed surplus of \$431,828 (2021 - \$837,909).

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 15. SHARE CAPITAL (continued)

The following table summarize information about the warrants outstanding and exercisable at June 30, 2022:

Exercise price per share	Expiry date	Number of warrants
1.00	February 8, 2024	306,060
1.20	November 30, 2023	1,000,000
1.50	February 8, 2024	3,350,000
1.80	May 31, 2023	602,080
		5,258,140
Weighted average remaining life		1.50 years

#### 16. RELATED PARTY TRANSACTIONS

Related parties consist of key management personnel, directors, and entities that are associated with the Company as well as significant shareholders, including Orca Holdings, LLC ("Orca") which is owned by Mr. Randy Johnson, a director of the Company. The Company has defined key management personnel as senior executive officers, as well as the Board of Directors. The total remuneration of key management personnel and the Board of Directors was as follows:

		Six month period ended June 30, 2022		Six month period ended June 30, 2021
Director's fees	Ś	109,500	Ś	101,500
Share-based payments to directors	*	47,022	Ψ.	5,947
Key management short-term benefits		238,544		175,637
Share-based payments to key management		37,618		14,913
	\$	432,684	\$	297,997

Key management short-term benefits include all salary, bonuses, and health/dental benefits earned by officers during the period.

During the six-month period ended June 30, 2022, the Company paid \$171,151 (2021 - \$179,475) in legal fees to Miller Thomson LLP. Mr. Geoff Clarke, a director of the Company, is a partner of that law firm. Payments made by the Company to Miller Thomson LLP are for the various legal services provided to the Company by several lawyers and law clerks at the firm, which includes lawyers and law clerks in multiple provinces and offices across Canada.

On November 29, 2021, the Company amended a secured loan agreement with Orca for which the maturity date was extended 24 months to November 30, 2023 and the Company issued 1,000,000 warrants to Orca with an exercise price of \$1.20 and an expiry date of November 30, 2023. The loan with Orca is further described in note 13.

All related party transactions were valued at the exchange amount agreed to between the parties.

#### 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Assets and liabilities measured at fair value in the consolidated financial statements are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate fair values. The three levels of fair value hierarchy are:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 Inputs that are not based on observable market data.

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

The fair value hierarchy of assets and liabilities measured at fair value of the consolidated statements of financial position are disclosed in the notes to the financial statements is as follows:

	J	une 30, 2022		December 31, 2021					
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3			
Financial assets:									
Marketable securities	1,250	-	-	1,000	-	-			
Financial liabilities:									
Convertible debenture - conversion option	-	(19,979)	-	-	(199,904)	-			

#### Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with the financial liabilities that are settled by delivering cash or another financial asset.

The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due and to continue to fund its exploration and evaluation activities, and advance the Company's RapidSX<sup>™</sup> technology. The Company's accounts payable and accrued liabilities are due within six months. Their contractual cash flow is equal to their carrying value. Short term deposits are held in interest bearing instruments that can be converted to cash without penalty at any time and are recorded at fair value.

The following are the contractual maturities of the financial liabilities and other commitments. The table includes undiscounted cash flows of financial liabilities, including lease liabilities and other commitments, interest and principal cash flows based on the earliest date on which the Company is required to pay.

				Total							
	(	Carrying	C	Contractual							
June 30, 2022		Amount	C	Cash Flows	2022	2023	2024	2025	2026	>20	26
Interest - lease liabilities	\$	-	\$	14,566	\$ 8,531	\$ 6,035	\$ -	\$ -	\$ -	\$	-
Principal repayments - lease											
liabilities		134,627		134,627	48,455	86,172	-	-	-		-
Interest - convertible											
debentures		-		86,389	47,450	38,939	-	-	-		-
Principal - convertible											
debentures		1,255,000		1,255,000	-	1,255,000	-	-	-		-
Interest - long-term debt		-		158,599	55,976	102,623	-	-	-		-
Principal repayments - long-											
term debt		1,243,914		1,243,914	-	1,243,914	-	-	-		-
Total long-term debt		2,633,541		2,893,095	160,412	2,732,682	-	-	-		-
Trade and other payables		1,307,408		1,307,408	1,307,408	-	-	-	-		-
Total	\$	3,940,949	\$	4,200,503	\$ 1,467,820	\$ 2,732,683	\$ -	\$ -	\$ -	\$	-

#### Market risk

Market risk is the risk of loss that may arise from changes in market factors such as foreign currency rates, interest rates, and commodity and equity prices.

#### Foreign currency risk

A significant portion of the Company's transactions occur in United States dollars and accordingly, the related financial assets and liabilities are subject to fluctuations in the respective exchange rates. To limit exposure to this risk, cash and short-term investments are primarily held with high quality financial institutions in Canada.

Notes to Condensed Interim Consolidated Financial Statements For the three and six month period ended June 30, 2022

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

#### 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

The Company's exposure to US dollar currency risk as measured in Canadian dollars was as follows:

	2022	2021
Cash	\$ 4,278	292,212
Otherasset	65,111	55,995
Accounts payable and accrued liabilities	(617,106)	(65,679)
Loan payable	(1,148,779)	(1,103,025)
	\$ (1,696,496)	(820,497)

A 10% change in the US dollar exchange rate would affect net and comprehensive loss and deficit by \$169,650 (2021 - \$82,050).

Interest rate risk

The Company has cash held in a high interest savings account, as is the case at June 30, 2022. The Company does not have any debt that bears variable interest rates.

#### 18. SUPPLEMENTARY CASH FLOW INFORMATION

	June 30, 2022 \$	June 30, 2021 \$
Non-cash financing and investment activities:		
Accounts payable and accrued liabilities related to resources		
properties and related exploration costs	504,899	(413)
Prepaids related to resource properties and related exploration costs	3,570	4,761
Reversal of reserves relating to the exercise of warrants	-	22,695
Shares issued on conversion of convertible debentures	-	1,980,053
Reversal of reserves relating to the expiration of warrants	431,828	447,852
Warrants issued on conversion of convertible debentures	-	624,470

#### 19. SUBSEQUENT EVENTS

## (i) Line of Credit Facility

On July 20, 2022, the Company secured a line of credit facility in the amount of up to \$2,000,000 USD. Proceeds from the line of credit will primarily be used to continue the development of the Company's RapidSX<sup>TM</sup> rare-earth element commercial demonstration plant. The line of credit has been extended by Orca Holdings, LLC ("Orca"). In consideration for granting the line of credit, two million warrants were issued to Orca, with each warrant entitling Orca to acquire one common share of the Company at an exercise price of \$0.75 during a one-year term ending on July 20, 2023.

Drawdowns on the line of credit will be available in multiples of \$100,000 USD and will carry interest at a rate of 9% per annum. All amounts owing under the line of credit will be repayable by January 20, 2023, unless such repayment is accelerated by the Company completing a significant equity financing prior to that date. The line of credit is secured by a general security agreement over the assets of the Company.

## (ii) Stock Option Grant

On August 9, 2022, the Company granted an aggregate of 2,325,000 stock options to directors, officers, employees and consultants of the Company. The options are exercisable into common shares at a price of \$0.85 per share and the options expire five years from August 9, 2022, the date of grant. One third of the options will vest after six months, with one third vesting every six months thereafter until fully vested.

On August 21, 2022, 810,000 options (which had been granted on August 21, 2017) expired unexercised. See note 15(b).